Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV after MEC, but not superior in preventing delayed CINV after HEC. Emetogenicity was classified by Hesketh criteria; this reanalysis uses newer American Society of Clinical Oncology criteria.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Future Oncol

Title: Future oncology (London, England)

Publisher: Future Medicine Ltd

ISSN (Electronic): 1744-8301

ISSN (Print): 1479-6694

Publication date (Electronic): Sep 2015

Volume: 11

Issue: 18

Affiliations

[1 ] Merck & Co, RY34-B2114, Mailstop B270, 126 East Lincoln Avenue Rahway, NJ 07065, USA.

[2 ] At the time of writing this article: Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Road, Lake Success, NY 11042, USA.

[3 ] Center for Cancer & Blood Disorders, 6410 Rockledge Drive #660, Bethesda, MD 20819, USA.

[4 ] TFS International, 70 Church Street, Flemington, NJ 08822, USA.

[5 ] FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA.

[6 ] Albert Einstein College of Medicine, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, USA.

Article

DOI: 10.2217/fon.15.185

PubMed ID: 26289588

SO-VID: f727ccf3-1148-464f-87f2-0d568ab3e5cd

History

Keywords: APF530,cancer,chemotherapy-induced nausea and vomiting,extended-release,granisetron,subcutaneous

Data availability:

Keywords: APF530, cancer, chemotherapy-induced nausea and vomiting, extended-release, granisetron, subcutaneous

Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.

Read this article at

Abstract

Related collections

Cancer Metabolism

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 316

Cited by 2